A microfluidic platform for systems pathology: multiparameter single-cell signaling measurements of clinical brain tumor specimens.

  title={A microfluidic platform for systems pathology: multiparameter single-cell signaling measurements of clinical brain tumor specimens.},
  author={Jing Sun and Michael Masterman-Smith and Nicholas Alexander Graham and Jing Jiao and Jack Mottahedeh and Dan R. Laks and Minori Ohashi and Jason DeJesus and Ken-ichiro Kamei and Ki-Bum Lee and Hao Wang and Zeta Tak For Yu and Yi-Tsung Lu and Shuang Hou and Keyu Li and Max Liu and Nangang Zhang and Shutao Wang and Brigitte Ang{\'e}nieux and Eduard H. Panosyan and Eric R. Samuels and Jun K Park and Dirk Williams and Vera Konkankit and David Nathanson and R. Michael van Dam and Michael E. Phelps and Hong Wu and Linda M. Liau and Paul S. Mischel and Jorge A. Lazareff and Harley I. Kornblum and William H. Yong and Thomas G. Graeber and Hsian‐Rong Tseng},
  journal={Cancer research},
  volume={70 15},
The clinical practice of oncology is being transformed by molecular diagnostics that will enable predictive and personalized medicine. Current technologies for quantitation of the cancer proteome are either qualitative (e.g., immunohistochemistry) or require large sample sizes (e.g., flow cytometry). Here, we report a microfluidic platform-microfluidic image cytometry (MIC)-capable of quantitative, single-cell proteomic analysis of multiple signaling molecules using only 1,000 to 2,800 cells… 

Figures from this paper

Microfluidic image cytometry.

Microfluidic image cytometry (MIC) is utilized and demonstrated, capable of quantitative, single-cell profiling of multiple signaling molecules using only 300-3,000 cells from clinical brain tumor specimens for in vitro molecular diagnosis.

Microfluidic Single-Cell Proteomics Assay Chip: Lung Cancer Cell Line Case Study

A microfluidic chip for a single-cell proteomics assay that is capable of analyzing complex cellular signaling systems to reveal the heterogeneity of cancer cells is proposed and suggests a new method for selecting the best combination of anti-cancer drugs.

Single Cell Proteomics for Molecular Targets in Lung Cancer: High-Dimensional Data Acquisition and Analysis.

Aside from deciphering disease mechanisms, single-cell proteomic techniques facilitate the identification and screening of biomarkers, molecular targets and promising compounds as well.

Quantitative single cell heterogeneity profiling of patient derived tumor initiating gliomaspheres reveals unique signatures of drug response and malignancy

Quantitative single cell heterogeneity profiling resolves signaling diversity into meaningful non-obvious phenotypic groups suggesting EGFR is decoupled from AKT/TORC1 signalling while identifying potentially valuable targets for personalized therapeutic approaches for deadly tumor-initiating cell populations.

Integrated microfluidic and imaging platform for a kinase activity radioassay to analyze minute patient cancer samples.

An immunocapture-based in vitro kinase assay on an integrated polydimethylsiloxane microfluidics platform that can reproducibly measure kinase activity from as few as 3,000 cells is developed and it is shown that the resulting integrated device can measure ABL kinases activity from BCR-ABL-positive leukemia patient samples.

Clinical Applications of NanoVelcro Rare-Cell Assays for Detection and Characterization of Circulating Tumor Cells

The authors will briefly introduce the development of three generations of NanoVelcro CTC Assays, and highlight the clinical applications of each generation for various types of solid cancers, including prostate cancer, pancreatic cancer, lung cancer, and melanoma.

Organ-Tumor-on-a-Chip for Chemosensitivity Assay: A Critical Review

A cutting edge system would be able to completely evaluate the absorption, distribution, metabolism, excretion and toxicity of anticancer drugs and more realistically recapitulate tumor in vivo-like microenvironment.

Microfluidics-based single-cell functional proteomics for fundamental and applied biomedical applications.

An emerging microfluidics-based toolkit for single-cell functional proteomics is reviewed, discussing the history and challenges of the field, and design concepts and uses of the microchip platforms that have been reported, with an eye toward biomedical applications.

Microchip platforms for multiplex single-cell functional proteomics with applications to immunology and cancer research

This work discusses advances in single-cell proteomics platforms, with an emphasis on microchip methods, and examples of how those platforms are being applied to both fundamental biology and clinical studies, focusing on immune-system monitoring and phosphoprotein signaling networks in cancer.



Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens

A nanofluidic proteomic immunoassay (NIA) to quantify total and low-abundance protein isoforms in nanoliter volumes for the development of new therapeutics for cancer.

Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling

Using FCB and phospho-specific flow cytometry, a small-molecule library for inhibitors of T cell–receptor and cytokine signaling is screened, simultaneously determining compound efficacy and selectivity.

Microfluidic chips for detecting the t(4;14) translocation and monitoring disease during treatment using reverse transcriptase-polymerase chain reaction analysis of IgH-MMSET hybrid transcripts.

Diagnosis platforms incorporating low-cost microfluidic chips enable sensitive, rapid, and accurate genetic analysis that could facilitate customized therapies tailored to match the vulnerabilities

Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma

The results suggest that the clinical use of c-Met kinase inhibitors in combination with either EGFR inhibitors or standard chemotherapeutics might represent a previously undescribed therapeutic approach to overcome the observed chemoresistance in patients with GBMs expressing EGFRvIII.

High Content Cell Screening in a Microfluidic Device*S

A microfluidic device that enables quantitative interrogation of signaling networks in thousands of individual cells using immunofluorescence-based readouts is described and it is shown that NF-κB activity dynamics in individual cells are not asynchronous and instead resemble the dynamics of the population average in contrast to studies of cells overexpressing p65-EGFP.

Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells

Nanotechnology and cancer.

The goal of the presentation is to identify nanotherapeutic strategies that are designed to increase efficacy while simultaneously minimizing the toxic side effects commonly associated with cancer chemotherapies.

Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo.

The first dissection of the PI3K pathway in glioblastoma in vivo is provided and an approach to stratifying patients for targeted kinase inhibitor therapy is suggested.

Simultaneous measurement of multiple active kinase states using polychromatic flow cytometry

Polychromatic flow-cytometric active kinase measurements demonstrate that multidimensional analysis of signaling pathways can provide functional signaling pathway assessment on a single-cell level and allow for potential correlation with biological and clinical parameters.